NCT01481194

ACVDL Treatment for Patients With Newly Diagnosed Multiple Myeloma

An Open-Label Phase II Study of the Safety and Efficacy of Doxorubicin and Cyclophosphamide in Combination With Bortezomib, Lenalidomide, and Dexamethasone for Treatment of Patients With Newly Diagnosed Multiple Myeloma

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 35 (actual)
• Sponsor: Vejle Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the efficacy and safety of the combination treatment of doxorubicin, cyclophosphamide, bortezomib, dexamethasone, and lenalidomide in newly diagnosed multiple myeloma patients.

Conditions

• Multiple Myeloma

Interventions

Type	Name	Description
DRUG	Doxorubicin	50 mg/m2 IV on day 1 of a 21-day cycle
DRUG	Bortezomib	1.3 mg/m2 IV push on days 2 and 9 of a 21-day cycle
DRUG	Lenalidomide	15 mg orally on days 1-14 of a 21-day cycle
DRUG	Dexamethasone	20 mg orally on days 2, 3, 9, and 10 of a 21-day cycle
DRUG	Cyclophosphamide	750 mg/m2 IV on day 1 of a 21-day cycle

Timeline

• Start date: 2011-11-01
• Primary completion: 2014-05-01
• Completion: 2018-08-28
• First posted: 2011-11-29
• Last updated: 2019-03-01

Locations

1 site across 1 country: Denmark